Besides the first generation Chimeric antigen receptor (CARs), Creative Biolabs also constructs CellRapeutics™ second generation CARs products with high quality. Our skilled scientists have rich experience in constructing CARs of different generations, which offers you the world leading service.
Sjoukje J. C. van der Stegen, Mohamad Hamieh & Michel Sadelain. The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery 14, 499–509 (2015)
Second-generation CARs architecture comprises an antigen binding domain, a hinge or spacer region, a transmembrane domain (TM) and an endodomain. The antigen binding domain is usually derived from a single-chain variable fragment (scFv) which recognizes and binds tumor specific antigens. The hinge domain links the antigen binding domain with TM. It provides sufficient flexibility to facilitate antigen binding. The application of a hinge in CARs is depended on the type of the antigen. With our extensive experience, we can design an appropriate hinge within CARs to achieve an optimal T cell response.
The first generation CARs has only one endodomain (intracellular signaling region) like CD3ζ. It is designed to activate T cell and induce cytolysis. However, it cannot perform a long term response. To overcome this, the second generation CARs which consist of the activating and the co-stimulatory signal domains are designed. Compared to the former generation, this generation CARs compose a single costimulatory region derived from either CD28 or 4-1BB in addition to CD3ζ. In preclinical and early clinical investigations, the second generation CARs have performed more prolonged polyclonal expansion and antitumor effect.
With advanced techniques and seasoned scientists, Creative Biolabs can offer full line of CARs products targeting many malignant tumor antigens. We provide the first-class service which is tailored to meet your needs and goals.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE